182 related articles for article (PubMed ID: 33026651)
1. Investigation of drug resistance against protease, reverse transcriptase, and integrase inhibitors by next-generation sequencing in HIV-positive patients.
Tekin D; Gokengin D; Onay H; Erensoy S; Sertoz R
J Med Virol; 2021 Jun; 93(6):3627-3633. PubMed ID: 33026651
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Transmitted Drug Resistance among HIV-1 Patients in the Aegean Region: Results from the Western Part of Turkey.
Sertoz R; Tekin D; Erensoy S; Biceroglu S; Kaptan F; Köse S; Ozkan H; Cetin B; Türken M; Gokengin D
Curr HIV Res; 2023; 21(2):109-116. PubMed ID: 37231747
[TBL] [Abstract][Full Text] [Related]
3. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay.
Alidjinou EK; Coulon P; Hallaert C; Robineau O; Meybeck A; Huleux T; Ajana F; Hober D; Bocket L
J Clin Virol; 2019 Dec; 121():104207. PubMed ID: 31707202
[TBL] [Abstract][Full Text] [Related]
4. Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors.
Dalmat RR; Makhsous N; Pepper GG; Magaret A; Jerome KR; Wald A; Greninger AL
J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30305383
[TBL] [Abstract][Full Text] [Related]
5. Comparison of an
Tzou PL; Ariyaratne P; Varghese V; Lee C; Rakhmanaliev E; Villy C; Yee M; Tan K; Michel G; Pinsky BA; Shafer RW
J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29618499
[TBL] [Abstract][Full Text] [Related]
6. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
[TBL] [Abstract][Full Text] [Related]
7. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
[TBL] [Abstract][Full Text] [Related]
8. Performance of the Applied Biosystems HIV-1 Genotyping Kit with Integrase.
Moore HP; Palumbo PJ; Notarte KI; Fogel JM; Cummings V; Gamble T; Del Rio C; Batey DS; Mayer KH; Farley JE; Remien RH; Beyrer C; Hudelson SE; Eshleman SH;
J Clin Microbiol; 2024 Jun; 62(6):e0013624. PubMed ID: 38727213
[TBL] [Abstract][Full Text] [Related]
9. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.
Palmer S; Kearney M; Maldarelli F; Halvas EK; Bixby CJ; Bazmi H; Rock D; Falloon J; Davey RT; Dewar RL; Metcalf JA; Hammer S; Mellors JW; Coffin JM
J Clin Microbiol; 2005 Jan; 43(1):406-13. PubMed ID: 15635002
[TBL] [Abstract][Full Text] [Related]
10. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
11. Analytical Assessment of the Vela Diagnostics NGS Assay for HIV Genotyping and Resistance Testing: The Apulian Experience.
Bonifacio MA; Genchi C; Lagioia A; Talamo V; Volpe A; Mariggiò MA
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269868
[TBL] [Abstract][Full Text] [Related]
12. Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance Testing.
Weber J; Volkova I; Sahoo MK; Tzou PL; Shafer RW; Pinsky BA
J Mol Diagn; 2019 Nov; 21(6):961-970. PubMed ID: 31382033
[TBL] [Abstract][Full Text] [Related]
13. Added Value of Next Generation over Sanger Sequencing in Kenyan Youth with Extensive HIV-1 Drug Resistance.
Novitsky V; Nyandiko W; Vreeman R; DeLong AK; Manne A; Scanlon M; Ngeresa A; Aluoch J; Sang F; Ashimosi C; Jepkemboi E; Orido M; Hogan JW; Kantor R;
Microbiol Spectr; 2022 Dec; 10(6):e0345422. PubMed ID: 36445146
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
[TBL] [Abstract][Full Text] [Related]
15. Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV.
Climaco-Arvizu S; Flores-López V; González-Torres C; Gaytán-Cervantes FJ; Hernández-García MC; Zárate-Segura PB; Chávez-Torres M; Tesoro-Cruz E; Pinto-Cardoso SM; Bekker-Méndez VC
BMC Infect Dis; 2022 May; 22(1):447. PubMed ID: 35538426
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.
Fisher RG; Smith DM; Murrell B; Slabbert R; Kirby BM; Edson C; Cotton MF; Haubrich RH; Kosakovsky Pond SL; Van Zyl GU
J Clin Virol; 2015 Jan; 62():48-53. PubMed ID: 25542470
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 drug resistance in newly infected individuals.
Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
[TBL] [Abstract][Full Text] [Related]
18. Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.
Weber J; Vazquez AC; Winner D; Rose JD; Wylie D; Rhea AM; Henry K; Pappas J; Wright A; Mohamed N; Gibson R; Rodriguez B; Soriano V; King K; Arts EJ; Olivo PD; Quiñones-Mateu ME
Antimicrob Agents Chemother; 2011 Aug; 55(8):3729-42. PubMed ID: 21628544
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
